A recent SEC filing details that Michael Feld, who serves as Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co., disposed of shares in the company's common stock on May 26, 2026. The transaction involved the sale of 75 shares at a price point of $147.35 per share, resulting in a total divestiture value of $11,051.
The filing specifies that this particular sale was executed under the framework of a Rule 10b5-1 trading plan, a mechanism Mr. Feld initially adopted on February 7, 2025. Notably, the realized sale price of $147.35 was in close proximity to the stock's prevailing market price of $147.22. Furthermore, the reported share price was positioned below InvestingPro’s Fair Value estimate, which suggests a potential undervaluation of the company's stock.
The financial data for Becton Dickinson reveals several strong indicators of operational health and corporate stability. In its Q2 2026 earnings report, the medical technology firm surpassed market expectations. The adjusted earnings per share (EPS) came in at $2.90, exceeding the forecast of $2.78. Revenue also demonstrated strength, reaching $4.7 billion, which was slightly higher than the anticipated figure of $4.67 billion.
Beyond standard quarterly results, Becton Dickinson undertook a significant financing activity. Its subsidiary, Becton Dickinson Euro Finance S.à r.l., finalized an underwritten public offering amounting to €600 million in notes due in 2033. These notes are fully and unconditionally guaranteed by the parent company, BD.
The company's growth strategy is also evident through product expansion and leadership changes. Becton Dickinson introduced the Elyra Thulium Fiber Laser System, a new offering designed for urologic stone management and soft tissue procedures. This system is available in two distinct configurations to accommodate varying operational requirements.
In terms of organizational structure, BD appointed Peter Menziuso as executive vice president and president of BD Interventional, an appointment effective June 1. Mr. Menziuso brings experience from Johnson & Johnson, where he previously managed a global business valued at $5 billion. These developments collectively illustrate Becton Dickinson's ongoing strategic initiatives and robust financial performance.
Regarding insider holdings, following the recent sale, Michael Feld maintains a direct ownership stake of 21,084 shares of Becton Dickinson common stock.
Risks
- <p>The article does not explicitly detail specific financial or operational risks associated with the recent sales or corporate strategies.</p>
- impact_analysis_sector_market_1: Medical Technology Sector - The focus on advanced systems (Elyra Laser) and strong earnings suggests continued demand in the healthcare space.</li>
- <p>The article does not explicitly detail specific financial or operational risks associated with the recent sales or corporate strategies.</p>
More from Insider Trading
Risks
- <p>The article does not explicitly detail specific financial or operational risks associated with the recent sales or corporate strategies.</p>
- impact_analysis_sector_market_1: Medical Technology Sector - The focus on advanced systems (Elyra Laser) and strong earnings suggests continued demand in the healthcare space.</li>
- <p>The article does not explicitly detail specific financial or operational risks associated with the recent sales or corporate strategies.</p>